Somerville, NJ – March 13, 2017 – Today, Ethicon* and DePuy Synthes are joining forces to introduce customized wound closure kits for orthopaedic surgery. The new wound closure kits, which include Ethicon’s innovative wound closure products STRATAFIX™ Knotless Tissue Control Devices and DERMABOND® PRINEO® Skin Closure System, allow for complete customization and are now available through DePuy Synthes in the U.S.
As the need for standardization and efficiency in the operating room becomes increasingly important, these customized wound closure kits may help health systems meet their Triple Aim goals of reducing costs, enhancing patient outcomes and increasing patient satisfaction.
Orthopaedic surgeons are now able to choose which sutures they would like by each layer of closure, packaged in one convenient kit for specific procedures, designed to provide standardization and efficiency in the operating room. The advanced technology of STRATAFIX Knotless Tissue Control Devices and DERMABOND PRINEO System also helps to achieve greater procedural efficiencies during wound closure. The Ethicon wound closure kits will be assembled and supplied by Medical Action Industries, an Owens & Minor Company, a leading provider of procedure-based kits and trays.
“DePuy Synthes’ extensive reach in the orthopaedics space will enable us to bring the benefits of Ethicon’s advanced wound closure products to many more health systems and sites of care,” says Gary Fischetti, Company Group Chairman, North America Region, Johnson & Johnson Medical Devices Companies. “The launch of our wound closure kit demonstrates just one of the new ways we are partnering across our medical devices businesses to provide efficient capabilities that streamline procedures, and may lead to better outcomes for the millions of patients who undergo surgery each year.”
The Benefits of Advanced Wound Closure Technology
With its latest wound closure innovations, STRATAFIX Knotless Tissue Control Devices and DERMABOND PRINEO System, Ethicon continues to lead the way in wound closure that is helping to improve efficiencies in the OR, reduce wound closure time and optimize healing for patients. STRATAFIX Knotless Tissue Control Devices provide more strength and security, more consistency and more efficiency than traditional suture.i The portfolio of STRATAFIX Knotless Tissue Control Devices also enables surgeons to more easily manage tension and control tissue approximation with each pass during closure and eliminates the need to tie knots.i As a replacement for sutures or staples, DERMABOND PRINEO System provides minimally invasive closure – no holes in the skin; no sutures or staples to remove, and no dressing changes, which may potentially reduce follow-up visits and support good cosmetic results for patients.ii,iii
STRATAFIX Knotless Tissue Control Devices and DERMABOND PRINEO System also offer the additional benefits of addressing some of the risk factors associated with Surgical Site Infections (SSIs). Addressing the risk factors associated with SSI’s has never been more important, now that the costs resulting from some hospital-acquired infections are no longer reimbursed by Medicare. The DERMABOND PRINEO System has been shown in vitro to provide a microbial barrier that provides protection against organisms commonly responsible for SSIs.iii The portfolio of STRATAFIX Knotless Tissue Control Devices offers sutures with Ethicon Plus antibacterial triclosan coating. Plus Sutures have been proven in vivo to kill bacteria on the suture known to be associated with SSIs.iv, v
For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.
About DePuy Synthes Companies
DePuy Synthes Companies, part of the Johnson & Johnson Family of Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes Companies solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.
From creating the first sutures, to revolutionizing surgery with minimally invasive procedures, Ethicon, part of the Johnson & Johnson Family of Companies, has made significant contributions to surgery for more than 60 years. Our continuing dedication to Shape the Future of Surgery is built on our commitment to help address the world’s most pressing health care issues, and improve and save more lives. Through Ethicon’s surgical technologies and solutions including sutures, staplers, energy devices, trocars and hemostats and our commitment to treat serious medical conditions like obesity and cancer worldwide, we deliver innovation to make a life-changing impact. Learn more at www.ethicon.com and follow us on Twitter @Ethicon.
* Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates. Ethicon, Inc. is the legal manufacturer of STRATAFIX™ and DERMABOND® PRINEO®. All other trademarks are the property of their respective owners.
i Data on file, Ethicon, Inc.: STRATAFIX Claims Matrix SFX-308-12. 2013.
ii Ethicon Inc. DERMABOND PRINEO Skin Closure System (22cm) Instructions for Use. LAB100114233v2. 5/15
iii Data on File, Ethicon Inc (2013) DERMABOND PRINEO Skin Closure System Matrix. 043364-151113
iv Ming X, Rothenburger S, Nichols MM. In vivo and invitro antibacterial efficacy of PDS Plus (polidioxanone with triclosan) suture. Surg Infect. 2008;9(4):451-457. v Ming X, Rothenburger S, Yang D. In vitro antibacterial efficacy of Monocryl Plus Antibacterial Suture (poligelcaprone 25 with triclosan). Surg Infect. 2007;8(2):201-207.